期刊文献+

内蒙古地区蒙古族VKORC1-1639 G/A和CYP2C9基因多态性与华法林应用剂量关系的研究 被引量:5

Study of VKORC1 and CYP2C9 Plymorphism on Dosage of Warfarin in Atrial Fibrillation Patients in Inner Mongolian Area
下载PDF
导出
摘要 目的探讨内蒙古地区蒙古族维生素K环氧化物还原酶复合物1(VKORC1)-1639 G/A及CYP2C9基因多态性分布特点及对华法林应用剂量的影响。方法选择300例蒙古族心房颤动病人(蒙古族组)和300例汉族心房颤动病人(对照组),PCRRFLP法检测两组VKORC1-1639 G/A及CYP2C9基因型分布,同时记录华法林剂量及国际标准化比值(INR)。计算不同VKORC1及CYP2C9基因型间平均校正华法林剂量。结果蒙古族组VKORC1-1639 AA、AG、GG基因型分布频率分别为78%、18%、4%;等位基因A和G频率分别为87%、13%。对照组VKORC1-1639 AA、AG、GG基因型分布频率分别为79%、19%、2%;等位基因A和G频率分别为86%、14%。蒙古族CYP2C9*1/*1型276例,CYP2C9*1/*3型24例。汉族CYP2C9*1/*1型279例,CYP2C9*1/*3型21例。不同VKORC1、CYP2C9基因型房颤病人华法林用量不同,VKORC1 AA型并CYP2C9*1/*1型和VKORC1 AG型并CYP2C9*1/*1型病人华法林日用量均高于VKORC1 AA型并CYP2C9*1/*3型病人;VKORC1 AG型并CYP2C9*1/*1型病人华法林用量高于VKORC1 AA型并CYP2C9*1/*1型病人,3组比较,差异有统计学意义(P<0.05)。结论蒙古族与汉族基因型VKORC1-1639 G/A及CYP2C9一致,多态性均为VKORC1-1639 AA及CYP2C9*1/*1型均占多数,不同基因型影响个体间华法林的维持应用剂量。 Objective To investigate the relationship between vitamin K oxide reductase complex subunit 1( VKORC1)-1639 G / A and cytochrome P450( CYP) 2C9 genetic polymorphicmand warfarin dosage in inner Mongolian populations. Methods The patients with atrialfibrillationwere divided into two groups: Mongolian group(n = 300,Mongolian populations) and compared group(n = 300,Han populations).PCR-RFLP were used to analysis the VKORC1-1639 G / A and CYP2C9 genetic polymorphism,and the international normalized ratio( INR)in every patients were recorded. The mean warfarin dosage was compared according to different VKORC1 genotypes. Resluts The frequencies of the VKORC1-1639 AA,AG,GG genotypes in the Mongolian patient group were 78%,18% and 4%,and 76. 5%,19%,4. 5% in compared group. The alleles frequencies of VKORC1-1639 A and G were 87% and 13% in the Mongolian patient group,and 86% and 14% in compared group(P = 0. 26). The maintenance doses of warfarin was( 2. 98 ± 1. 6) mg / d in AA genotype group,( 3. 67 ± 1. 8) mg / d in AG genotype group and( 4. 36 ± 2. 0) mg / d in GG genotype,respectively. There were 276 patients were CYP2C9 * 1 / * 1,24 patients were CYP2C9* 1 / * 3 in the Mongolian patient,279 patients were CYP2C9* 1 / * 1,21 patients were CYP2C9* 1 / * 3 in the compared group.There was a significantly different among different VKORC1 and CYP2C9 genotypes patients(P〈0. 05). The dosage in CYP2C9 * 1 / * 1with VKORC1 AG patients were higher than the other groups,and the dosage in CYP2C9* 1 / * 1 with VKORC1 AA were higher than that in CYP2C9 * 1 / * 3 with VKORC1 AA groups. Conclusion There was no significant difference ingenotype distribution of VKORC1-1639 G / A and CYP2C9 between the Mongolian patients and the Chinese Han population patient,but the VKORC1-1639 AA,AG,GG and CYP2C9* 1 /* 1,CYP2C9* 1 / * 3 genotypes influent the warfarin dosage.
出处 《中西医结合心脑血管病杂志》 2016年第20期2340-2344,共5页 Chinese Journal of Integrative Medicine on Cardio-Cerebrovascular Disease
关键词 华法林 维生素K环氧化物还原酶复合物1 细胞色素P450酶2C9 基因多态性 蒙古族 warfarin vitamin K oxide reductase complex subunit 1 cytochrome P450 2C9 genetic polymorphism Mongolian
  • 相关文献

参考文献3

二级参考文献35

  • 1王志伟,徐明星,计乐群.心脏瓣膜置换术后低强度抗凝研究[J].中华实验外科杂志,2005,22(4):484-485. 被引量:21
  • 2蒋年新,宋杰,徐标.维生素K环氧化物还原酶复合体1基因多态性对华法林维持剂量的影响[J].中华心血管病杂志,2007,35(7):652-654. 被引量:5
  • 3Fuster V, Ryden LE, Asinger RW, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary. A Report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines and the
  • 4Hirsh J, Dalen J, Anderson DR, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest, 2001,119(1 Suppl):8S-21S.
  • 5Levine MN, Raskob G, Landefeld S, et al. Hemorrhagic complications of anticoagulant treatment. Chest, 2001,119(1 Suppl):108S-121S.
  • 6The stroke prevention in atrial fibrillation investigation. Bleeding during antithrombotic thearapy in patients with atrial fibrillation. Arch Intern Med, 1996, 156:409-416.
  • 7Fihn SD, Callahan CM, Martin DC, et al. The risk for and severity of bleeding complications in elderly patients treated with warfarin. The National Consortium of Anticoagulation Clinics. Ann Intern Med, 1996,124:970-979.
  • 8Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med,1994,120:897-902.
  • 9Stroke prevention in atrial fibrillation investigators. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke prevention in atrial fibrillation Ⅲ randomized clinic trial. Lan
  • 10Ridker PM, Goldhaber SZ, Danielson E, et al. Long-term, low-intensity warfarin therapy for the prevention of reccurrent venous thromboembolism. N Engl J Med, 2003,348:1425-1434.

共引文献178

同被引文献32

引证文献5

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部